In short
A groundbreaking clinical trial is underway to evaluate the effectiveness of M2Rlab, a modified autologous leukocyte cell therapy, in treating acute kidney injury (AKI) following cardiac surgery. This phase II study aims to assess the safety, efficacy, and optimal dosage of M2Rlab compared to a placebo in patients who develop AKI within 48 hours after heart surgery. The trial focuses on improving renal function recovery time and reducing complications associated with AKI in this vulnerable patient population.
At a glance
- Drug Name
- M2Rlab (Mononuclear cells M2RLAB)
- Type of Therapy
- Modified autologous leukocyte cell therapy
- Condition Treated
- Acute kidney injury after cardiac surgery
- Trial Phase
- Phase II
- Administration
- Intravenous injection, max 10 ml daily dose
- Primary Objectives
- Assess renal function recovery time, reduce persistent kidney problems, evaluate safety
- Key Eligibility
- Adults 18+, undergoing cardiac surgery, high AKI risk, develop AKI within 48h post-surgery
- Main Outcomes Measured
- Kidney function recovery, need for dialysis, hospital stay duration, survival rates
What is M2RLAB?
M2RLAB is an innovative cell therapy being studied for the treatment of acute kidney injury (AKI) in patients who have undergone cardiac surgery. This therapy uses modified autologous leukocyte cells, which means it's made from a patient's own white blood cells that have been specially processed. M2RLAB is classified as a biological and advanced therapy medicinal product, indicating its cutting-edge nature in medical treatment.
Medical Condition: Acute Kidney Injury (AKI) After Cardiac Surgery
Acute kidney injury is a sudden decrease in kidney function that can occur after major surgeries, especially heart surgeries. This condition can be serious and may lead to complications, extended hospital stays, and in some cases, the need for dialysis. M2RLAB is being developed specifically to address AKI that develops within 48 hours after cardiac surgery.
How M2RLAB Works
M2RLAB is administered intravenously (through a vein) as an injectable solution. The therapy uses a patient's own white blood cells (leukocytes) that have been modified to potentially help repair and protect the kidneys after injury. While the exact mechanism is still being studied, it's believed that these modified cells may help reduce inflammation and promote healing in the damaged kidney tissue.
Clinical Trial Details
M2RLAB is currently being evaluated in a Phase II clinical trial. This stage of research aims to assess both the safety and effectiveness of the treatment, as well as determine the best dosing regimen. The study is comparing M2RLAB to a placebo in patients who develop AKI within 48 hours after cardiac surgery.
The main goals of the trial include:
- Measuring how quickly kidney function recovers in patients treated with M2RLAB compared to placebo
- Assessing the safety and tolerability of the treatment
- Evaluating the need for and duration of dialysis in treated patients
- Comparing the length of hospital and intensive care unit (ICU) stays between treated and untreated patients
- Analyzing survival rates and kidney function at 30 and 90 days after treatment
Eligibility Criteria
Not all patients with AKI after cardiac surgery will be eligible for this trial. Some key inclusion criteria are:
- Adults over 18 years of age
- Undergoing elective heart valve and/or coronary surgery with extracorporeal circulation (a machine that temporarily takes over the function of the heart and lungs during surgery)
- Having a high risk (≥30%) of developing AKI after surgery, based on a specific assessment scale
- Developing AKI within 48 hours after surgery, confirmed by blood and urine tests
Patients with certain conditions may not be eligible, including those with severe kidney disease before surgery, very poor heart function, or those who have had a kidney transplant.
Potential Benefits of M2RLAB
While the effectiveness of M2RLAB is still being studied, the researchers hope to see several potential benefits, including:
- Faster recovery of kidney function after AKI
- Reduced need for dialysis
- Shorter stays in the ICU and hospital
- Improved survival rates at 30 and 90 days after treatment
- Lower risk of developing chronic kidney problems
Safety and Side Effects
As with any new treatment, safety is a primary concern. The clinical trial is closely monitoring for any side effects or complications that may arise from M2RLAB treatment. Specific areas being watched include:
- Infectious complications
- Surgery-related complications
- Changes in heart function
- Any unexpected adverse events
It's important to note that as M2RLAB is still in the research phase, all potential risks and benefits are not yet fully known. Patients considering participation in the clinical trial should discuss the potential risks and benefits thoroughly with their healthcare providers.